Three-year data from the Phase Ib trial of BOT+BAL was unveiled at ESMO GI 2026.

BERLIN -- In a global phase III trial, the addition of durvalumab (Imfinzi) to standard chemotherapy given before and after surgery led to a statistically significant and "clinically meaningful" ...

The 12-month survival rates in patients with non-clear cell renal cell carcinoma showed improvements after treatment with Yervoy plus Opdivo. A treatment combination with Yervoy (ipilimumab) plus ...

Bavencio and Inlyta combination therapy demonstrated high six- and 12-month OS rates in advanced RCC patients in real-world settings. The AVION study confirmed the combination's safety, with 83.7% ...

Peri-operative treatment patterns in real-world muscle-invasive bladder cancer patients undergoing radical cystectomy in the era of adjuvant immunotherapy. Recurrence and OS by stage and treatment ...